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Abstract
p66Shc, a 66 kDa proto-oncogene Src homologous-collagen homologue (Shc) adaptor protein, is
classically known in mediating receptor tyrosine kinase signaling and recently identified as a
sensor to oxidative stress-induced apoptosis and as a longevity protein in mammals. The
expression of p66Shc is decreased in mice and increased in human fibroblasts upon aging and in
aging-related diseases, including prostate cancer. p66Shc protein level correlates with the
proliferation of several carcinoma cells and can be regulated by steroid hormones. Recent
advances point that p66Shc protein plays a role in mediating cross-talk between steroid hormones
and redox signals by serving as a common convergence point in signaling pathways on cell
proliferation and apoptosis. This article first reviews the unique function of p66Shc protein in
regulating oxidative stress-induced apoptosis. Subsequently, we discuss its novel role in androgen-
regulated prostate cancer cell proliferation and metastasis and the mechanism by which it mediates
androgen action via the redox signaling pathway. The data together indicate that p66Shc might be
a useful biomarker for the prognosis of prostate cancer and serve as an effective target for its
cancer treatment.
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1 Introduction
Cell proliferation and apoptosis are the two indispensable physiologically balanced,
associated, and regulated cellular processes [1]. Disruption in this homeostasis forms the
basis for several life-threatening diseases, for example, cancer, neurodegenerative, and
autoimmune diseases [2–4]. The foremost and fundamental mechanism that governs these
two processes is the signal transduction machinery that is mediating this process [1,5,6].
Adaptor proteins are in general signaling molecules lacking enzymatic activity while they
have the ability to interact with other proteins mediating cell signaling. The prototype Src
homologue and collagen homologue (Shc) adaptor proteins were cloned by using an SH2-
coding sequence as a probe, and this family of proteins includes three members with
molecular masses of 46, 52, and 66 kDa, which are encoded by the same gene at
chromosome 1q21 [7]. The Shc adaptor protein has been considered as one of the most
studied adaptor proteins for exploring the role of adaptor proteins in cellular signaling;
therefore the role of Shc proteins in mediating diverse signaling pathways has received
much attention [7–11]. The expression of these adaptor proteins, especially p66Shc, might
be regulated by steroid hormones [10] that play a distinct role in the regulation of tumor
development, cancer cell proliferation, progression, and metastatic processes of major types
of cancers [12]. Moreover, cross-talks between tyrosine phosphorylation signaling and
steroid hormones have been well established [13–17]. It is now evident that either in the
early stage of carcinogenesis or in the advanced metastatic phenotype, steroid hormone
action goes far beyond the classical receptor-mediated gene regulation. These steroid
hormone-related cancers share some common mechanisms of carcinogenesis, such as DNA
damage/mutation and aberrant growth regulation due to the elevated levels of various
growth factors induced by the excess of steroids [18–20].
Growth factors and their receptors are known to be involved in regulating various steps of
carcinogenesis, including cell proliferation, motility, invasion and/or migration of various
cell types [21–29]. The activated receptors triggered by growth factors, cytokines or
adhesion molecules facilitate the docking of Shc adaptor molecules, containing Src
homology 2 (SH2) and phosphotyrosine-binding (PTB) domains, which transduce signals to
downstream intracellular cascades. Thus, Shc proteins play a conceivable role in various
stages of carcinogenesis.
Moreover, several lines of evidence indicate that Shc proteins mediate diverse biological
activities other than merely serve as adaptors in tyrosine phosphorylation signaling. One
such functional role of Shc proteins, specifically p66Shc, is in mediating redox signaling and
thus is deserving further studies ever since it is reported to play a prominent role in oxidative
stress-induced apoptosis and the life span of mammals. [30]. Other Shc members have also
been implicated in the longevity and apoptosis of C. elegans and Drosophila [31,32].
Indeed, p66Shc expression is decreased in mice with advanced age and is reduced in mouse
lung cells upon treatment with aurintricarboxylic acid that promotes cell survival, suggesting
p66Shc as one of the lifespan determinants in mammals [33].
Aberrant expression of p66Shc could also be involved in various stages of carcinogenesis
[9,10,34–38]. Despite the fact that Shc proteins could be differentially phosphorylated in
different types of primary tumors and tumor cell lines [28,39,40], a direct correlation
between the protein level of p66Shc and prostate cancer cell proliferation is observed,
insisting the importance of p66Shc adaptor protein in the tumorigenicity of human prostate
cancer [10,41,42]. Thus, in the light of above facts, the present review will emphasis both
the extremities of p66Shc adaptor protein, including its apoptotic potential in the control of
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lifespan in mammals and its novel role in androgen-regulated prostate cancer cell
proliferation and metastasis and the mechanism by which it mediates the androgen action via
redox signaling pathway.
2 p66Shc —a unique isoform of ShcA adaptor protein
p66Shc is an isoform of ShcA family of adaptor proteins, transcribed from a promoter in the
first intron of Shc locus [43]. It contains four functional domains, a SH2 domain (ᙺ100
amino acids) at the COOH-terminal that mediates the formation of multiprotein complexes
during signaling [44,45] and a PTB binding domain, which is separated by a collagen
homology (CH1) domain, enriched in proline and glycine residues and contains the essential
tyrosine phosphorylation sites (Fig. 1) [7,9]. Structurally, p66Shc differs from p52Shc and
p46Shc by virtue of its unique NH2-terminal, a 110-amino acid CH2 region, which is also
rich in proline and glycine residues and contains the inimitable serine phosphorylation (S36
& S54) sites [8]. In addition to these domains, p66Shc also carries a cytochrome c-binding
(CB) region within the CH2-PTB domains that is primarily implicated in the mitochondrial
regulation of oxidative stress [46].
2.1 Ambiguous presence of p66Shc
Unlike the ubiquitous expression of p52Shc and p46Shc isoforms, p66Shc expression is
vastly constrained that may be due to the utilization of two alternative promoters and the
selective regulation of the transcriptional inclusion of the N-terminal CH2 domain, which is
specific for p66Shc [47]. p66Shc is expressed primarily in epithelial cells [8] whereas its
expression is missing or very stumpy in neurons, hematopoietic cell lines and peripheral
blood lymphocytes, and further its expression varies in breast and prostate cancer cell lines
[7,34,40,41,48]. Intriguingly, peripheral blood lymphocytes, mouse thymocytes and splenic
T-cells attain the ability to express p66Shc in response to oxidative stress stimuli [49], which
might be attributed to the transcriptional regulation of p66Shc gene promoter.
2.2 Tweaking of p66Shc expression
The p66Shc protein level can be regulated at the levels of post-translation and transcription.
The post-translational modifications of p66Shc protein include protein phosphorylation and
prolyl-isomerization. For example, serine 36 (S36) phosphorylation of p66Shc upon
oxidative stress results in shift in the mobility of p66Shc protein in SDS-gels in various cell
types [30,50–53] and also rac1-mediated phosphorylation of S54 in the CH2 domain and
T386 in the CH1 domain of p66Shc (Fig. 1) causes decreased p66Shc protein turnover by
disguising their proteolytic PEST signal sequence that can be recognized by the
ubiquitin-26S proteasome degradative pathway [54]. The later event of post-translational
modification also implicates the substantial role of rac1 in the stability of p66Shc. Cis-trans
isomerization of phosphorylated p66Shc at S36 by Prolyl isomerase can result in a
conformational change that facilitates the transfer of p66Shc from cytosol to mitochondria in
mouse embryo fibroblasts (MEFs) [55]. A S36-phosphorylation independent pathway has
also been established for the translocation of p66Shc from cytosol to mitochondria induced
by androgens in prostate cancer cells [42], which will be discussed later.
Regulation of p66Shc expression at the transcriptional level includes the silencing of p66Shc
by epigenetic modifications of its promoter such as DNA methylation and histone
deacetylation. Evidently, the expression of p66Shc is restored in primary, immortal and
transformed cells upon treatments of histone deacetylase inhibitors and demethylation
agents, and also an inverse correlation is observed between p66Shc promoter methylation
and its expression in the cell lines expressing various amounts of p66Shc [43,56]. This
methylation disparity in the p66Shc promoter is consecutively involved in the process of
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both aging and tumorigenesis, as age-related methylation possibly serves as a basic marker
in cancer subjects [57–61]. Strikingly, it has been found that the promoter methylation does
not have any influence on the p66Shc expression level in the centenarians; while the p66Shc
expression in these subjects is affected by p53 codon 72 polymorphism following oxidative
stress [62]. Studies by Mooijaart et al. [63] exemplify the correlation of the Met410Val
polymorphism in p66Shc gene with the regulation of lifespan in humans. However, the
contradictions in the relationship of p66Shc expression in cellular senescence need further
investigations.
2.3 Tyrosine phosphorylation of p66Shc
ShcA proteins are the targets of receptor tyrosine kinases (RTKs) and are concerned in the
transmission of mitogenic signals to Ras [7]. In this context, like other isoforms of p52Shc/
p46Shc, p66Shc is also tyrosine phosphorylated by RTKs upon growth factor stimulation
and binds effectively to Grb2, while it is unable to activate the Ras-MAPK-Fos pathways
and also unable to transform NIH3T3 mouse fibroblasts [8,30]. Indeed, over expression of
p66Shc result in the inhibition of Ras signaling pathway in response to EGF or to cytokines
[8,49,53]. p66Shc also inhibits the IGF-1 stimulation of MEK/ERK pathway that is required
for actin cytoskeleton phosphorylation in skeleton muscle myoblasts [64]. The possible
explanation for the inhibitory effect of p66Shc on mitogenic signaling are (1) upon growth
factor (e.g., EGF) stimulation, p66Shc competes with p52Shc/p46Shc isoforms for binding
to the limited cellular pool of Grb2 and seizes the Grb2/SOS complex, but is unable to
recruit SOS, thus results in the dominant negative inhibition of p52Shc/p46Shc–mediated
MAPK pathway (Fig. 2). (2) The reason could also be that increased expression of p66Shc
has resulted in an elevated basal activity of ERK/MAPK in the absence of stimulus, which
thus minimizes the extent of further activation by growth factors such as EGF [41]. (3)
Serine/threonine phosphorylation of p66Shc that takes place upon EGF stimulation and
following tyrosine phosphorylation is proposed to be crucial for the termination of Ras/
ERK/MEK pathways as this event may uncouple the association of p66Shc·Grb2 complex
from EGFR via forming the nonproductive complex with Grb2 (Fig. 2) [49,53]. Further, the
inhibitory effect on the c-fos promoter activation by p66Shc is primarily mediated by the N-
terminal CH2 domain rather than by the critical CH1 domain; the later is in common with
the p52Shc/p46Shc mediated Ras-signaling [8]. These facts further exploit the functional
importance of the unique N-terminal CH2 domain of p66Shc and it could be proposed that
p66Shc plays a role independent of Ras pathway.
2.4 Serine phosphorylation of p66Shc
The major serine phosphorylation sites of p66Shc are S36 and S54 in its CH2 domain and
S138 in the PTB domains (Fig. 1). Several stimuli that are engaged in tyrosine
phosphorylation of p66Shc also trigger the phosphorylation of S138 in the PTB domain
[65]. The S54 site in the CH2 domain of p66Shc is found to be critical for the stability of
p66Shc [54]. The S36 site is unique to p66Shc isoform and is responsible for oxidative
stress response whereas the S138 site is homologous to S29 in p52Shc that is regulated by
PKC and MEK1 (Fig. 1) [65,66]. Further, S36 phosphorylation of p66Shc has also been
shown to exert a pro-apoptotic effect in different cell types. The variation in the responses of
S36 phosphorylation both in vivo and in vitro depend on the kinase(s) (MAPK, stress-
activated JNK and p38) that mediate this process that may vary depending on the cell type,
cellular milieu and the distinctiveness of the inducement [50,52,53,67].
Rapid phosphorylation on S36 is observed upon EGF and H2O2 treatments in fibroblasts.
Significantly, p66Shc ᙐ/ᙐ cells are unable to restore the pro-apoptotic response to H2O2
upon expression of p66S36A mutant into these cells, thus substantiating the role of S36
phosphorylation in inducing apoptosis [30]. Severe oxidative stress induces ERK/JNK-
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dependent S36 phosphorylation of p66Shc in renal proximal tubule cells that causes cell
death via negative feedback inhibition of Ras/MEK/ERK survival pathway by the early
activation of ERK and JNK [68]. In Chinese hamster ovary (CHO) cells, p66Shc negatively
regulates the EGF-induced Ras/Raf/MEK/ERK pathway via MEK-dependent S36
phosphorylation of p66Shc, which is followed by tyrosine phosphorylation of p66Shc [53].
Serine phosphorylation of p66Shc also takes place in response to other factors including
insulin, TPA, FGF-2, taxol and endothelin-1 [52,53,66,69]. Taxol-induced serine
phosphorylation of p66Shc in both macrophage-like cell line (RAW 264.7) and in non-
macrophage-like human cell line (human lung carcinoma cells-A549) stimulates the
signaling cascade that lead to cell death in a MEK-dependent and MEK-independent
manner, respectively, via inducing TNF-Į expression in RAW 264.7 cells and inducing
PARP cleavage in A549 cells [52,67]. In CHO cells, insulin also induces MEK-dependent
S36 phosphorylation of p66Shc and results in the inactivation of Ras [51] in a manner
similar to the insulin-stimulated MEK-dependent SOS phosphorylation [70]. Nevertheless,
the biological significance of insulin-induced S36 phosphorylation of p66Shc in these cells
is unclear.
It has been reported that serine phosphorylation of p66Shc promotes the binding of p66Shc
to the sequestering protein 14-3-3 and protein-tyrosine phosphatase (PTP) PEST [71].
Endothelin-1-induced serine phosphorylation in glomerular mesangial cells promotes the
binding of p66Shc to the sequestering protein 14-3-3 in a MEK/ERK dependent pathway
and exerts an anti-apoptotic effect [65]. It is thus proposed that this may occur via seizing
the apoptosis-inducing protein BAD, i.e., Bcl-xL/Bcl-2 associated death promoter, by the
sequestering protein 14-3-3 from mitochondria to cytosol [72]. Moreover, serine
phosphorylation of p66Shc by endothelin-1 through ERK has been reported to inhibit
apoptosis in vascular smooth muscle cells [73]. Nevertheless, it is unclear whether S36 or
S138 or both is the requisite for binding of p66Shc to the sequestering protein. On the
contrary, in NIH3T3 fibroblasts, TPA-induced S138 phosphorylation in the PTB domain of
p66Shc leads to p66Shc·Grb2 association and the activation of ERK [69] that is indirectly
promoted by the binding of p66Shc to PTP-PEST in a PKC-dependent manner [66].
However, the functional role of TPA-induced S138 phosphorylation of p66Shc has not been
clearly shown and further incompatibility persists with the binding of p66Shc to PTP-PEST
[74,75]. These facts therefore imply the inevitable role of p66Shc serine phosphorylation in
regulating both apoptosis and cell survival.
3 p66Shc and oxidative stress
Several lines of evidence for p66Shc and its pivotal play in the oxidative stress response
result from the information on p66Shc-null mice showing enhanced resistance to oxidative
stress in vivo upon treatment with paraquat, and amazingly, the p66Shcᙐ/ᙐ mice have a 30%
increase in their life span when compared with their normal animals [30]. Consistently,
p66Shcᙐ/ᙐ mice show reduced levels of systemic (isoprostane) and tissue (nitrotyrosines, 8-
oxo-dG) oxidative stress markers [76–79] and the enhanced resistance to oxidative stress
induced by hypercholesterolemia (atherogenesis) [78], acute ischemia [80], angiotensin II
[81], carbon tetrachloride [46] and ethanol [82]. Migliaccio et al. [30] have established the
critical role of p66Shc in the regulation of oxidative stress. p66Shc inhibits the c-fos
promoter activity triggered upon UV irradiation and by H2O2 [83], while the effect of
p66Shc on stress response is found to be in a dissimilar manner. Upon exposure of mouse
embryo fibroblasts (MEFs) to UV, H2O2 and EGF, EGF stimulated the tyrosine
phosphorylation whereas UV and H2O2 induced serine phosphorylation of p66Shc, thus
suggesting its role in redox signaling. This notion was supported by inducing apoptosis in
p66Shc-ablated and -over expressing MEFs via UV and H2O2 treatments. It is observed that
p66Shcᙐ/ᙐ cells have enhanced resistance to apoptosis, whereas over expression of p66Shc
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increases the sensitivity to apoptosis [30,77]. In fact, several p66Shcᙐ/ᙐ cells in general
show increased resistance to apoptosis upon other different signals, such as, growth factor
deprivation, taxol, calcium ionophore and CD3-CD4 cross-linking [49], staurosporine
[46,84] and amyloid-ȕ peptide [85]. The oxidative damage induced by p66Shc is attributed
to serine phosphorylation (S36) in its CH2 domain as oxidative damage causes the activation
of serine/threonine kinases [86]. Therefore, taken together these facts further exploit the
apoptotic potential of p66Shc that could act as a sensor of intracellular ROS concentrations.
3.1 p66Shc and p53—interplay
It was initially proposed that the oxidative stress response of p66Shc is mediated by the
tumor suppressor p53, as p53 is upregulated upon UV and H2O2 treatments and further like
p66Shcᙐ/ᙐ cells, p53ᙐ/ᙐ MEFs showed resistance to UV- and H2O2-induced apoptosis
[30]. This was confirmed by the studies of Trinei et al. [77] demonstrating that p66Shc
serves as a downstream effector of p53. A significant and incessant increase of p66Shc was
observed upon augmented expression of p53 in both WT MEFs and in the DLD-1 colon
cancer cells, the later possesses inactive p53, thus insisting the requisite of p53 for the
upregulation of p66Shc and consecutively is accomplished by increasing the stability of
p66Shc[77]. Further, the apoptotic function of p53 is mediated through a p66Shc dependent
manner, to be precise, p66Shcᙐ/ᙐ MEFs showed resistance to apoptosis induced by
increased expression of p53, and a simultaneous increase in apoptosis was observed in the
p53-activated DLD-1 cells upon mounting the expression of p66Shc in these cells. In
addition, p66Shc regulates the p53-dependent apoptosis but does not involve in other
functions of p53 such as cell cycle arrest [77]. Activation of p53 induces redox-related
genes, release of cytochrome c from mitochondria and promotes apoptosome assembly,
which ultimately lead to a persistent increase in the ROS levels [87–89]. p66Shcᙐ/ᙐ MEFs
were unable to trigger cytochrome c release, while p53 is activated upon H2O2 treatment,
whereas the deficit was restored upon re-expression of p66Shc in these cells, suggesting the
involvement of p66Shc in the regulation of p53-induced cytochrome c release. Further,
p66Shcᙐ/ᙐ cells failed to increase the ROS levels upon increasing the expression of p53;
while there was a marked increase in the ROS levels after expression of p66Shc in p66Shcᙐ/
ᙐ MEFs and p53-null DLD-1 cells, supporting the pivotal role of p66Shc and p53 in the
regulation of intracellular ROS levels yet in the absence of apoptogenic stimuli [77].
Fascinatingly, Tiberi and coworkers [90] have demonstrated that p53-independent S36
phosphorylation of p66Shc and a marked increase of oxidative stress-induced apoptosis
upon expression of p66Shc in p53ᙐ/ᙐ human cell lines, such as, Saos-2 and Hela cells.
Furthermore, several studies on the role of p66Shc in embryo arrest validate that p66Shc and
oxidative stress are associated with a p53-independent early embryonic arrest in vitro [91–
95].
3.2 p66Shc and forkhead proteins—interplay
The regulation of intracellular levels of ROS by S36-phosphorylated p66Shc is further
mediated by modulating the transcriptional activity of Forkhead (FKHD) transcriptional
factor FKHRL1 that is similar to the FKHD family member DAF-16, which regulates
lifespan in C. elegans [76]. FKHRL1 serves as a downstream target of activated p66Shc and
is vital for initiating tolerance to stress and cell survival [76]. Further, though it has been
contemplated that the cell survival and apoptotic effects of FKHD proteins depends on cell-
specific effect and/or gene-dosing effect, too high or too low FKHD protein may both lead
to cell death [96,97]. Several studies have demonstrated the association of FKHRL1
activation and apoptosis by serum and growth factor stimulation in lymphocytes [98],
whereas in fibroblasts and neuronal cells, p66Shc plays a pivotal role in the regulation of
FKHRL1 activity upon exposure to oxidative stress [76]. Further, FKHRL1 has been
reported to stimulate the antioxidant enzymes including superoxide dismutase and catalase
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and also in the release of pro-apoptotic protein such as Bim [76,99,100]. Accordingly, in
dormant cells, FKHRL1 is localized in the nucleus and is engaged in the control of the
expression of the antioxidant enzymes, such as catalase. Upon phosphorylation of FKHRL1
by oxidative stress, it is translocated to the cytoplasm and becomes inactive. Considering the
role of p66Shc in this task, p66Shcᙐ/ᙐ MEFs articulated an augmented resistance to H2O2
induced apoptosis via increasing the FKHRL1-transcriptional activity and consequently,
inducing the expression of antioxidant genes [76]. Thus substantiating the crucial act of
p66Shc in the oxidative stress-dependent inhibition of FKHRL1 transcriptional activity and,
subsequently, in the regulation of intracellular ROS levels and in the ageing process.
Nevertheless, the transcriptional control of FKHRL1 by p66Shc needs further analysis.
3.3 p66Shc in mitochondrial control of apoptosis
The increased intracellular ROS alters the mitochondrial membrane potential, leading to the
activation of mitochondrial permeability transition pore (MPTP) and the release of
cytochrome c [46,77,84]. Cyclosporin A, an inhibitor of MPTP and apoptosis, retarded the
oxidative stress-induced apoptosis in p66Shc-expressing wild type MEFs and also averted
the capability of re-expressed p66Shc to regain the H2O2-induced apoptosis in p66Shcᙐ/ᙐ
cells, suggesting the requirement of p66Shc in the regulation of MPTP and it also revealed
that MPTP serves as a downstream target of p66Shc [77]. Therefore, it is apparent that
p66Shc regulates oxidative stress in part through H2O2 generation that is involved in
mitochondrial control of apoptosis. Due to the importance of apoptosis involving in
carcinogenesis, the functional role of p66Shc in this mode of regulation has received much
attention and thus will be discussed in the following sub-sections. In light of current findings
and understandings, the possible role of p66Shc in oxidative stress-induced apoptosis is
summarized in Fig. 3.
3.3.1 S36-phosphorylation—a critical key for p66Shc translocation to
mitochondria—Most of the p66Shc protein is distributed throughout the cytosol and a
fraction of p66Shc localizes within the inner membrane and intermembrane space of
mitochondria and, oxidative stress stimulates an increase in the mitochondrial p66Shc
[46,84,101,102]. However, the mechanism by which p66Shc translocates into mitochondria
remains unclear. It is possible that p66Shc translocates into the mitochondria by the
influence of ER mitochondrial network such as inositol 1,4,5-triphosphate-dependent Ca2+
release channel [103]. Further, mitochondrial Ca2+ uptake is altered by protein kinase C (ȕ)
(PKC) [104], which is sensitive to oxidative stress [105]. Although S36 phosphorylation is
critical for apoptotic potential of p66Shc, mitochondrial p66Shc is not phosphorylated,
suggesting the nonmitochondrial role of S36 phosphorylation of p66Shc in manipulating the
pro-apoptotic response. Pinton and coworkers [55] have proposed a marked interdependence
between the PKCȕ-dependent phosphorylation of p66Shc and the early mitochondrial
responses to oxidative stimulus in MEFs, such responses include mitochondrial
fragmentation and repression of Ca2+ signal transmission to the mitochondria, pursued by
apoptosis. Accordingly, p66ShcS36A mutant was deficient in triggering the early
mitochondrial response to oxidative stress induced by PKCȕ activation, thus implicating the
requisite of S36 phosphorylation of p66Shc in the control of mitochondrial oxidative
response. In addition, Pellegrini et al., [106] have reported that Ca2+-dependent S36
phosphorylation of p66Shc is essential for mitochondrial dysfunction and impairment of
Ca2+ homeostasis, which encourages T cell apoptosis. Nevertheless, the mitochondrial
apoptotic responses mediated by p66Shc, in part, but not firmly depend on increase in
[Ca2+]c [cytosolic free Ca2+ concentration] [106]. The phosphorylated p66Shc is then
translocated to the mitochondria, which is mediated by binding of phosphorylated p66Shc to
a peptidyl-prolyl isomerase Pin1 [55]. Pin1 stimulates cis-trans isomerization of
phosphorylated Ser-Pro bonds (pSer-Pro); granting phosphorylation-dependent
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conformational change that is pertinent for the translocation of p66Shc to mitochondria.
Further, it has been reported that phosphatase PP2A recognizes and dephosphorylates pSer-
Pro, once isomerized by Pin1 [55,107]. However, the subcellular location of
dephosphorylation by phosphatase PP2A remains further investigation.
3.3.2 Mitochondrial super complex import machinery—a driving source for
p66Shc translocation—In the intermembrane space, mitochondrial p66Shc is associated
with the high-molecular-weight complex involving import machinery, namely, translocase
of the outer membrane/translocase of the inner membrane (TOM/TIM) super complex
(TIM44, TIM20, TIM23, and mtHsp70) [84,108]. In the basal condition, the mitochondrial
p66Shc associates with the mitochondrial heat-shock protein (mtHsp70), which is a stress
response protein that protects cells from the oxidative stress-induced mitochondrial damage
[84]. The mtHsp70 is in complex with the mitochondrial import machinery TIM44 subunit
and regulates the import of proteins into mitochondrial vesicles. Upon oxidative stress
signals, including UVC and H2O2, mtHsp70 dissociates from TIM44, which may facilitate
the discharge of the monomeric p66Shc (active) that has been associated with TOM–TIM
complex, while the later process is affected by the variations in mitochondrial energetic
status [46,84,108]. Thus the data together signify the importance of mtHsp70 in retarding
the apoptotic potential of p66Shc [84], which is delicately tuned by both cytosolic stimulus
and intrinsic mitochondrial machinery.
3.3.3 Redox-active sequence of p66Shc and electron transfer in mitochondria
—Within the mitochondrial inter-membrane space, p66Shc oxidizes cytochrome c resulting
in the generation of H2O2 via transferring electrons from reduced cytochrome c to oxygen
and that increases the intracellular ROS levels. The N-terminal CH2-PTB regions of p66Shc
possessing a redox-active sequence (Fig. 1) have been implicated in the binding of
cytochrome c and in the transfer of electrons, and the mutation of amino acid residue(s)
within the redox region impairs this pro-apoptotic function of p66Shc, leaving unaltered the
other cellular effects of p66Shc such as binding to the activated receptors [46]. In fact,
recent report demonstrated the presence of two redox centers in CH2-PTB regions of
p66Shc including a copper-sensitive catalytic site for ROS formation and a regulatory
disulphide/thiol site arbitrating a reversible dimmer-tetramer switch [109].
3.3.4 p66Shc—induced oxidative damage—Increase in the level of ROS increases
the damage of cellular proteins, lipids, and DNA and the accumulation of this oxidative
cellular damage caused by ROS is apparently the primary origin of ageing, supportively,
mutations and deletions of both nuclear and mitochondrial DNA are common phenomena in
aged mammals [110–112]. In consistence with this notion, it has been illustrated that cells
derived from p66Shcᙐ/ᙐ mice showed reduction in both the oxidation of the C8 of guanine
(8-oxo-dG) (a most profuse form of oxidation-damaged nuclear DNA [113]) and in the
mutation of mitochondrial DNA. Moreover, the expression of p66Shc correlates with the
intensity of oxidative damage, which is greater in the lung, spleen, liver and skin, while
there is no marked oxidative damage observed in brain where p66Shc expression is absent
[77]. Thus collectively, it is apparent that decreased intracellular ROS is accountable for the
prolonged life span of p66Shc ᙐ/ᙐ mice.
4 p66Shc and human longevity
Interestingly, the studies on p66Shc expression and human longevity illustrate that p66Shc
expression in dermal fibroblasts increases with age [62], which is converse to the role of
p66Shc in the elongation of life span in mice [30,33]. The greatest level of p66Shc is found
in fibroblasts from centenarians upon oxidative stress when compared to fibroblasts from
old and young individuals. It is thus speculated to be an adaptive response exerted by the
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centenarians to oxidative cellular damage accumulated with age. Further, several reports
reveal the association between the increased expression (mRNA and protein) of p66Shc and
cellular senescence and oxidative stress up-regulation of ROS [114–116]. Nevertheless, the
molecular means by which p66Shc mediates aging responses in humans are obscure.
Overall the above facts emphasize the central role of p66Shc in ageing process via
regulating oxidative stress-induced apoptosis in mammals. On the other side, in vivo and in
vitro studies demonstrated that p66Shc regulates the mtDNA replication, following Ras-
induced cell proliferation, which is triggered by but not as such depending on Ras signaling
[117]. Indeed, p66Shc mutants that lack the ability to get phosphorylated at S36 or to induce
apoptosis that upon transferred into p66Shcᙐ/ᙐ MEFs were able to enhance mtDNA
content, suggesting the pioneering mechanism of p66Shc apart from its role in ROS
generation [117]. Moreover p66Shcᙐ/ᙐ old mice show marked reduction in the level of
tissue (liver, skin and muscle) mtDNA that has been found to be increased in the tissues of
the corresponding wild type (wt) old mice, enumerating the relation between ageing, p66Shc
and mtDNA replication [117,118]. Thus, the data taken together is insisting the role of
mtDNA replication in the regulation of cell proliferation involving Ras and p66Shc.
5 Role of p66Shc in prostate cancer cell proliferation and metastasis
In general, cell proliferation, migration and adhesion to the target tissues are the critical
steps that allow tumor cells to obtain the metastatic phenotype. Cell proliferation and
migration depend on intracellular signals transmitted by growth factors and adhesion
proteins within the extracellular matrix [119]. The common intracellular signaling molecules
involved in these processes include Rho family proteins and ERK cascades [119–122]. It is
now evident that p66Shc plays a crucial role in cell migration and adhesion in addition to its
role in mediating cell proliferation induced by growth factor receptor signaling [123,124].
These processes require the rearrangement of actin cytoskeleton, the formation of new
integrin substratum contacts, cell contraction and release of pre-existing cell-matrix contacts
[125].
Noteworthily, these data are clinically significant because in prostate cancer archival
specimens, p66Shc protein level is significantly higher in prostate adenocarcinomatous cells
than in adjacent benign glandular cells [10]. Similarly, the expression level of p66Shc is
elevated in estrogen-regulated tumors, including metastatic breast and ovarian and estrogen-
treated breast cancer cells, and also other tumors including thyroid tumors and may serve as
a useful prognostic marker for stage IIA colon cancer [10,34,38,126,127]. It should be noted
that some data showed that p66Shc protein is down-regulated in primary tumors of breast
cancer [36]. We will thus discuss the role of p66Shc in these processes and emphasize on
androgen regulation in prostate cancer cell proliferation and metastasis, as the growth and
progression of prostate cancer including advanced cancers are dependent on androgens and
the receptors.
5.1 p66Shc in prostate cancer cell proliferation
In tyrosine phosphorylation signal transduction pathway, p66Shc is conventionally known as
an adaptor protein and exhibits the distinct biological function compared to other Shc
isoforms. As aforementioned, p66Shc is unable to transform NIH3T3 mouse fibroblasts in
culture cells despite that it is phosphorylated at its tyrosine residues upon EGF stimulation
and forms complexes with Grb2 [30]. It also could not augment the activation of EGF-
induced extracellular signal-regulated kinases/mitogen-activated protein kinases (ERK/
MAPK) in cell cultures such as HeLa, CHO, and COS-1 cells [8,53]. As discussed above,
one reason could be that increased expression of p66Shc has resulted in an elevated level of
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the basal activity of ERK/MAPK even in the absence of stimulus, which thus minimizes the
extent of further activation by growth factors such as EGF [41].
p66Shc plays a critical role in mediating proliferation of epithelial cells. Strikingly, the
protein level of p66Shc closely correlates with the growth rate of prostate cancer cells. In
rapidly growing prostate cancer cells such as PC-3 and DU145 cells, p66Shc protein level is
approximately 4–13-folds of that in slow-growing LNCaP C-33 cells and is over 10-fold of
even slower-growing MDA PCa2b cells [41]. In the presence of androgens or EGF, in slow-
growing human prostate cancer LNCaP C-33 and MDA PCa2b cells, both the p66Shc
protein level and cell proliferation rate are increased, higher than the corresponding cells
cultured in the absence of stimulus [10]. In parallel, in estrogen-treated breast cancer MCF-7
cells, increased p66Shc protein concurs with accelerated cell growth [10]. Thus, p66Shc
protein level is associated with the epithelial cell growth.
The direct role of p66Shc protein in regulating the growth of prostate cancer cells is clearly
supported by both cDNA and siRNA approaches [41]. Elevated expression of p66Shc by
cDNA transfection correlates with increased cell proliferation. On the contrary, a decreased
cell growth rate is observed when p66Shc protein is knocked down by its siRNA. It should
also be noted that phosphorylation of S36 at p66Shc serves as a sensor of apoptotic pathway,
androgen-stimulated cell proliferation correlates with decreased S36 phosphorylation [42]
(Fig. 4). The data clearly establish the causal relationship of p66Shc protein with prostate
cell growth. Furthermore, p66Shc mediates growth stimulation by androgens and elevated
expression of p66Shc might lead to androgen-independent proliferation [42]. Collectively,
the data show that the elevated level of p66Shc protein in androgen-regulated prostate
cancer cells plays a critical role in up-regulating those cancer cell proliferation and thus
contributes to the tumorigenicity of those cancer cells. The role of p66Shc in this mode of
regulation requires further investigation.
5.2 p66Shc and integrin-associated signaling in angiogenesis
Integrins play vital roles in cancer progression via regulating various intracellular signaling
molecules those are essential for cell motility, cell survival and proliferation [128,129].
Among them, Įvȕ3 integrin is thought to play a crucial role in the metastasis of cancer cells
to bone marrow [130]. In prostate cancer cells, Įvȕ3 is expressed in bone foci-derived
human PC-3 cells, but not in lymph node foci-derived LNCaP cells [131]. Įvȕ3 integrin is
also expressed in breast and lung cancer cells that were originally derived from the bone
marrow aspirates, supporting a role of integrin signaling in bone metastasis
Recent studies revealed that Įvȕ3 integrin-associated signaling by influencing VEGF
expression regulates the growth of both prostate and breast tumors. The up-regulation of
VEGF expression depends on Įvȕ3 clustering where it promotes the recruitment of p66Shc
and subsequently the phosphorylation of ȕ3-associated p66Shc. Thus, phosphorylation of
p66Shc is a critical step for Įvȕ3-mediated potentiation of VEGF expression and tumor
vascularization [37]. Supportively, down-regulation of p66Shc inhibits VEGF expression as
well as the tumor growth and angiogenesis in vivo [37]. These findings provide insights into
the role of Įvȕ3 and p66Shc interaction as a regulator of angiogenesis.
5.3 Role of p66Shc in metastasis
p66Shc is apparently involved in tumor metastasis including cellular invasion, motility and
migration in different types of cancers. An association between the expression of p66Shc
and prostate cancer cell motility is observed, i.e., an elevated expression of p66Shc is
associated with increased motility of cDNA transfected slow growing LNCaP C-33 cells
[Yuan TC, Lin FF and Lin MF, unpublished data]. Furthermore, LNCaP C-81 and PC-3
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prostate cancer cells express higher levels of p66Shc and exhibit higher metastatic potential
than LNCaP C-33 cells in xenograft animals [41, Sebeger J and Lin MF, unpublished data].
Thus, p66Shc is apparently involved in prostate cell motility, an early step of metastasis [34]
and may play a role in androgen-regulated prostate cancer metastatic process.
In parallel, xenograft bone metastasis of breast cancer MDA-MB-231cell line expresses
p66Shc and its metastatic variant F-11 cells have a 3-fold higher level of p66Shc [34].
Increased expression of p66Shc in lymph-node positive breast cancers also correlates with
lymph node metastasis [34]. Supportively, higher levels of p66Shc are observed in breast
cancer specimens with higher metastatic potential [34]. Conversely, decrease in the Shc A
levels or the expression of a dominant-negative Shc A mutant blocked TGFȕ-induced
motility and the invasion of Neu/ErbB-2-expressing breast cancer cells [132]. Together, the
data indicate that Shc A is involved in regulating tumor cell metastasis. Recent studies with
transgenic mouse models have clearly validated the role of Shc A signaling in regulating the
carcinogenesis of breast epithelia [133]. The observations on the increased expression of
p66Shc in different cancer cell lines with higher metastatic ability emphasize the importance
of p66Shc as a potential therapeutic target in combating different types of cancers including
the prostate.
6 A novel mechanism: androgen action via p66Shc-dependent redox
signaling in prostate cancer cells
p66Shc mediates androgen-stimulated prostate cancer cell proliferation in part via a non-
genomic redox signaling pathway. In rapidly growing cells, including androgen-stimulated
PCa cells, increased oxidative stress might contribute to the elevated level of p66Shc protein
(Fig. 4). As discussed earlier, p66Shc protein can function as a stress sensor and is involved
in regulating intracellular level of reactive oxygen species (ROS) [77]. ROS mediates
diverse biological functions, including cell proliferation, adhesion, migration and apoptosis
(Fig. 4).
Steroid hormones, such as androgens, and growth factors, such as EGF, can all up-regulate
ROS production in cells and thereby promote cell proliferation [134,135]. The functional
role of ROS as a positive regulator of prostate cancer cells is at least in part by inhibiting the
PTPase activity and thus the corresponding RPTK can be activated [135–137] (Fig. 4). This
is in consistent with our findings that androgenic treatment of androgen-sensitive LNCaP
C-33 and MDA PCa 2b cells promotes cell proliferation in part via increasing p66Shc
protein level [10] and ROS production, leading to decreased cellular prostatic acid
phosphatase (cPAcP) activity, a PTPase exhibiting the growth inhibitory activity [138–140],
and increased ErbB-2 tyrosine phosphorylation [13,42].
Supportively, in prostate cancer archival specimens, the higher level of ROS correlates with
the higher proliferation index in cancerous cells than in non-cancerous cells [141].
Furthermore, androgens promote the translocalization of p66Shc via a S36-phosphorylation-
independent mechanism from cytosol into mitochondria where it interacts with cytochrome
c for ROS production because androgen treatment results in decreased S36 phosphorylation
and elevated p66Shc mitochondrial level [42] (Fig. 4). Supportively, the redox-negative
mutant p66Shc W134F could not increase ROS production nor growth promotion [42].
Additionally, p66Shc may also increase ROS production through Rac1-SOS signal pathway
[142], possibly leading to androgen-independent prostate cancer cell proliferation [143].
Since ROS may play a critical role in the various stages of prostate carcinogenesis including
the initiation and the progression of prostate cancer, anti-oxidants may be useful for this
cancer prevention [144] despite the initial insignificant results of Selenium and Vitamin E
Cancer Prevention Trial, which might be in part due to the usage of different forms of
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selenium compound [145]. The data collectively support the notion that p66Shc can mediate
the non-genomic steroid action on prostate cancer cell proliferation and carcinogenesis
including metastasis; while the molecular mechanisms require further investigations.
7 Potential clinical applications of p66Shc in prostate cancer and its
perspectives
To date, numerous factors such as cytokines, growth factors and receptors have been
demonstrated for their vital roles in the various stages of prostate carcinogenesis. Further
understanding the molecular mechanisms should pave ways to identify new prognostic
markers that might also serve as therapeutic targets for the prevention and treatment of
prostate cancer. In the journey of hunting surrogate markers for determining the prostate
origin of metastatic cancers, cPAcP prior to PSA was used as a biomarker, due to its cell-
specific expression [146,147]. Nevertheless, its cellular level negatively correlates with
prostatic carcinogenesis [139,147–150]. Recently, several studies have established the
marked effects of the adaptor protein p66Shc, a molecule that serves as a common
convergence point in signaling pathways on cancer cell proliferation, migration, metastasis,
and cell death, since the expression level of p66Shc increases with age and in age-related
diseases including cancer, especially prostate cancer [15,34].
In this review, we have outlined the striking role of p66Shc in mediating the oxidative
stress-induced apoptotic responses in general and discussed its functional role in cell growth,
survival, migration and ultimate metastasis of prostate cancer. The inflammation has been
proposed to play a critical role in prostate carcinogenesis. Our preliminary data reveal a
possible association of p66Shc protein expression with the atrophy of prostate epithelia (Lin
FF, Johansson SL and Lin MF, un-published observations) while the biological significance
remains further investigation. We also present a novel mechanism by which androgen
signaling via p66Shc, an authentic oxidase, promotes prostate cancer cell proliferation.
Interestingly, in prostate cancer cells, the level of p66Shc is inversely correlated with cPAcP
expression [139] and has a positive correlation with the activation of ErbB-2 as well as
ERK/MAPK [41]. This inverse correlation of cPAcP to p66Shc expression level and ErbB2
as well as ERK/MAPK activation is also clinically relevant [10,138,139,150–156]. Hence,
despite the fact that cPAcP alone may serve as a good prognostic marker for metastatic
prostate cancer [153]; because of decreased cPAcP level upon tumor progression as well as
increased p66Shc protein level in PCa tumors, we contemplate that the p66Shc/cPAcP ratio
may serve as a competitive surrogate biomarker for predicting the prognosis of prostate
carcinomas. Furthermore, this positive correlation to prostate cancer makes p66Shc a
soaring precedence therapeutic target for combating against the progression of prostate
cancer. Indeed, knockdown expression of p66Shc reduces the tumorigenicity of prostate
cancer cells [41,42].
In summary, we propose that the participation of p66Shc in cell proliferation and/or
apoptosis depends on the type of cell origin, the signals and kinases[s] that are involved in
the signal transduction network and as well the cellular milieu. In prostate cancer, p66Shc
plays a critical role in tumor progression, while the molecular mechanism of inverse
relationship between cPAcP and p66Shc protein and the upstream regulators and
downstream effectors engaged in p66Shc signaling pathway relating to androgens remain
further investigations. The results may identify p66Shc as a surrogate marker for the
prognosis of prostate cancer and lead to the development of novel therapy against prostate
cancer.
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Fig. 1.
A schematic organization of p66Shc. The p66Shc consists of a SH2 domain at the COOH-
terminal, three major tyrosine phosphorylation sites and a threonine phosphorylation site
within the central CH1 domain and a serine phosphorylation site (S138) in the PTB domain.
It also contains a unique CH2 domain [110 amino acids] comprising the serine
phosphorylation sites (S36 and S54) at the NH2-terminal. p66Shc also possesses a
cytochrome c-binding region (CB) within the CH2-PTB domains
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Fig. 2.
A possible mechanism for the inhibitory effect of p66Shc on mitogenic signaling. Upon
growth factor, e.g., EGF, stimulation, p66Shc competes with p52Shc/p46Shc isoforms for
binding to the limited cellular pool of Grb2 and seizes the Grb2/SOS complex, but is unable
to recruit SOS. Subsequently, serine 36 (S36) phosphorylation of p66Shc following tyrosine
phosphorylation uncouples the association of p66Shc·Grb2 complex from EGFR via
forming the nonproductive complex with Grb2, and thus may result in the dominant
negative inhibition of p52Shc/p46Shc-mediated Ras-MAPK pathway
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Fig. 3.
A schematic representation for the possible role of p66Shc in oxidative stress-induced
apoptosis. In the cytosol, p66Shc is phosphorylated at S36 upon oxidative stress and is
mediated by the activation of p53, kinases and also due to modulation in the calcium ion
concentration. The phosphorylated p66Shc is then translocated to the mitochondria by
binding to a peptidyl-prolyl isomerase Pin1. In the mitochondrial intermembrane space,
p66Shc associates to the mitochondrial super complex import machinery (TIM44, TIM20,
TIM23 & mtHsp70) at the basal state, whereas upon oxidative stress signals mtHsp70
dissociates from TIM44 and facilitates the discharge of p66Shc (active) that has been
associated with TOM-TIM complex. The monomeric p66Shc then interacts and oxidizes
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cytochrome c (cyt c) resulting in the generation of H2O2 via transferring electrons from
reduced cytochrome c to oxygen and that increases the intracellular ROS levels. The
increased intracellular ROS alters the mitochondrial membrane potential, leading to the
opening of MPTP, swelling of mitochondria, release of cytochrome c and finally result in
the mitochondrial fragmentation and apoptosis. The regulation of intracellular levels of ROS
by S36-phosphorylated p66Shc is further mediated by inhibiting the transcriptional activity
of the transcriptional factor FKHRL1
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Fig. 4.
p66Shc signaling and its novel mechanism regulated by androgens in prostate cancer cells.
Oxidative stress including androgen depletion, UV and H2O2 induces the phosphorylation
at S36 of p66Shc protein that leads to the increased production of ROS. The later mediates
diverse biological functions, including cell proliferation, adhesion, migration and apoptosis.
In prostate cancer cells, androgen (DHT) treatment also increases the ROS level via
increasing the p66Shc protein level and decreasing the S36-phosphorylation of p66Shc,
which lead to prostate cancer cell proliferation. p66Shc protein mediates androgen action on
tumor progression. Upon stimulation by androgens, p66Shc is translocated to mitochondria
via Ser-36 phosphorylation-independent manner resulting in the generation of ROS. ROS
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may then inhibit PTP, leading to corresponding RPTK activation and ERK/MAPK
activation. ROS may also activate ERK/MAPK directly. Together, this activated signal can
promote cell proliferation, survival as well as migration that collectively lead to tumor
metastasis
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